Myriad Genetics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 6, 2026, reporting a net loss of $43.9 million on revenue of $202.7 million for the third quarter.

Key Highlights

  • Q3 2026 Revenue: $202.7 million, compared to $205.7 million in Q3 2025, according to the filing.
  • Q3 2026 Net Loss: $43.9 million, or $0.46 per basic and diluted share, versus a net loss of $27.4 million, or $0.29 per share, in Q3 2025.
  • Nine-Month Net Loss: $121.2 million for the nine months ended September 30, 2026, compared to $358.0 million for the same period in 2025.
  • Cash Position: Cash and cash equivalents stood at $107.1 million as of September 30, 2026, down from $149.6 million at December 31, 2025.
  • Total Assets: $609.2 million as of September 30, 2026, compared to $706.6 million at December 31, 2025.
  • Accumulated Deficit: $1,243.9 million as of September 30, 2026, up from $1,122.7 million at December 31, 2025.
  • Shares Outstanding: 95,922,196 shares of common stock outstanding as of October 30, 2026.

Myriad Genetics Reports Third-Quarter and Nine-Month 2026 Financial Results

According to the Form 10-Q filed with the SEC, Myriad Genetics (NASDAQ:MYGN) reported revenue of $202.7 million for the three months ended September 30, 2026, a decrease from $205.7 million in the comparable prior-year period. Gross profit for Q3 2026 was $137.7 million, compared to $143.8 million in Q3 2025. The company reported an operating loss of $39.9 million for the quarter, widening from an operating loss of $23.3 million in Q3 2025, driven in part by an increase in sales and marketing expense to $83.9 million from $71.0 million year over year.

For the nine months ended September 30, 2026, the filing disclosed revenue of $593.8 million, down from $614.7 million in the nine months ended September 30, 2025. The nine-month operating loss narrowed significantly to $109.5 million from $381.5 million in the prior-year period, which the filing shows included $316.7 million in goodwill and long-lived asset impairment charges in 2025, compared to $5.4 million recorded in the first nine months of 2026. Nine-month net loss per basic and diluted share was $1.28 in 2026 versus $3.88 in 2025.

The condensed consolidated balance sheet as of September 30, 2026, reflected total stockholders' equity of $269.0 million, down from $368.0 million at December 31, 2025. Long-term debt was reported at $121.1 million, and total liabilities stood at $340.2 million. Stock-based compensation expense for Q3 2026 was $9.2 million, according to the statements of stockholders' equity. The company reported 95.7 million weighted average shares outstanding (basic and diluted) for Q3 2026.

What Was Disclosed

Myriad Genetics filed its quarterly report covering the period ended September 30, 2026, disclosing a Q3 net loss of $43.9 million on revenue of $202.7 million, reduced cash of $107.1 million, and an accumulated deficit of $1,243.9 million as of quarter end.